COPD – therapy/exacerbations

E-Posters in free access
Chairs: R. Stockley (Birmingham, United Kingdom), E. Russi (Zurich, Switzerland)

Providing reviews of evidence to people with chronic disease: controlled prospective study in COPD M. Harris, B. J. Smith, A. Veale, A. Esterman, P. A. Frith (Adelaide, Australia)
Initial anticholinergic therapy COPD E. Y. Pronina, A. A. Vizel (Kazan, Russian Federation)
The efficacy of salmeterol/fluticasone (SF) for 6-month therapy in severe COPD patients I. N. Trofimenko, B. A. Chernyak (Irkutsk, Russian Federation)
Effects of steroid treatment on serum leptin level and haemostatic parameters in COPD patients with normal body mass index E. Kunter, E. Demirer, Z. Kartaloglu, A. Ozturk, K. Avsar (Istanbul, Turkey)
The relationship between thyroid hormones, somatomedin-C (IGF-1), anabolic hormones and the severity of disease in chronic obstructive lung disease (COPD) F. Coskun, E. Ege, E. Uzaslan, D. Ediger, M. Karadag, O. Gozu (Bursa, Turkey)
Weaning of COPD patients from invasive mechanical ventilation: a comparison of four methods H. A. Makhlouf, G. M. Agmy (Assiut, Egypt)
Therapeutic response in COPD patients with CFTR R75Q variant and mEPHX "slow" allele – is there a difference? N. D. Petrovic, V. B. Dopudja, D. R. Ponomarev, Z. N. Slavkovic, M. M. Stankovic, A. M. Nikolic, A. I. Divac, R. P. Dragica (Belgrade, Serbia And Montenegro)
The therapeutic strategies in severe and very severe COPD: a cost-efficacy analysis in Italy R. W. Dal Negro, S. Iannazzo, L. Pradelli, M. Eandi (Bussolengo, Torino, Italy)
A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD) M. D. Filipovic, S. S. Cekic (Nis, Serbia And Montenegro)
The current situation and the perspective of respiratory home care in Japanese COPD patients: Japanese white paper for respiratory home care subanalysis J. Ueki, M. Takaya, K. Aoki, Y. Kodama, K. Fujimoto, H. Ishihara, K. Tatsumi, M. Mishima, K. Miyamoto, T. Kawashiro, Y. Fukuchi (Urayasu, Tokyo, Japan)
Different causes of COPD exacerbation: unable or not to use bronchodilator drugs and journey to high altitude M. Akgun, E. Yilmazel Ucar, O. Araz, M. Meral, A. Mirici (Erzurum, Turkey)
Calcium channels‘ blockers in therapy of COPD patients O. V. Myronenko (Dniepropetrovsk, Ukraine)
Are there any significant differences in the bacterial carrier of acute exacerbation of severe and very severe COPD according the degree of pulmonary functional impairment? L. M. Ristic, M. H. Rancic, M. A. Radovic, T. A. Pejcic, I. J. Stankovic (Nis, Serbia And Montenegro)
A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) A. Kwok, L. Davies (Liverpool, United Kingdom)
Identifying COPD patients at risk of frequent hospital admission J. Islam, D. Gibbons, J. Rimer, T. Wilkinson, J. Wedzicha, P. Dilworth (London, United Kingdom)
Do patients with an exacerbation of chronic obstructive pulmonary disease (COPD) really need to be admitted to a respiratory ward? M. I. Sulaiman, C. Lomax, S. Maredia, R. J. Stead, M. Babores (Macclesfield, United Kingdom)
Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline A. Damianaki, D. Makris, M. Kokosi, E. Ntaoukakis, N. M. Siafakas, N. Tzanakis (Heraklion, Greece)
Monocytes phagocytosis activity during remission and exacerbation of COPD J. A. Mikryukova, G. V. Ashyrov, G. L. Ignatova, L. A. Stepanisheva, A. S. Sarsenbaeva (Chelyabinsk, Russian Federation)
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD P. Golabi, N. Topaloglu, S. Karakurt, T. Celikel (Istanbul, Turkey)
Gram-negative enterobacteria in the etiological structure of COPD exacerbation E. Mishustina, T. Ageeva, S. Mishustin (Tomsk, Russian Federation)
Can treatment with tiotropium influence nitrate stress in the COPD patients? J. Musil, J. Chládek (Prague, Hradec Králové, Czech Republic)
The role bacterial and viral infection in COPD exacerbation E. P. Pejovic, L. Kezunovic, M. Batricevic, N. Kavaric (Podgorica, Serbia And Montenegro)
Serum uric acid levels among patients with COPD exacerbations Z. M. Lazic, V. B. Cupurdija, L. A. Novkovic, C. V. Ivan, O. M. Gajovic (Kragujevac, Serbia And Montenegro)
Prevalance of deep-vein thrombosis of the leg in acute exacerbations of COPD G. Pala, M. Kiyik, H. C. Tigin, E. Artan, T. Karadeli, S. Intepe, B. Kocak, H. Ozyurt, S. Cikrikcioglu (Istanbul, Turkey)
The character of COPD exacerbation G. V. Ashyrov, J. A. Mikryukova, G. L. Ignatova, E. V. Blinova, L. M. Chusova (Chelyabinsk, Russian Federation)
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years G. T. Ferguson, P. M. A. Calverley, J. A. Anderson, B. Celli, C. Jenkins, P. W. Jones, J. Vestbo, J. C. Yates, N. Pride (USA; United Kingdom; Australia)
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years B. Celli, P. M. A. Calverley, J. A. Anderson, G. T. Ferguson, C. Jenkins, P. W. Jones, J. Vestbo, J. C. Yates, N. Pride, on behalf of the TORCH investigators (USA; United Kingdom; Australia)
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years G. T. Ferguson, P. M. A. Calverley, J. A. Anderson, B. Celli, C. Jenkins, P. W. Jones, J. Vestbo, J. C. Yates, N. Pride, on behalf of the TORCH investigators (United States Of America; United Kingdom; Australia)